KRAS and NRAS mutation detection in circulating DNA from patients with metastatic colorectal cancer using BEAMing assay: Concordance with standard biopsy and clinical evaluation by Lastraioli, E. et al.
ONCOLOGY LETTERS  20:  15,  2020
Abstract. Patients with metastatic colorectal cancer (mCRC) 
are routinely screened for either K‑ and N‑RAS to select the 
appropriate treatment. The present study aimed to evaluate the 
concordance between K‑ and NRAS status in the tissue (either 
primary tumor or metastasis) and the plasma of patients with 
mCRC and to identify the associations between K‑ and NRAS 
mutations in ctDNA and the clinicopathological parameters. 
Samples from a total of 31 patients with mCRC with measur‑
able disease according to the Response Evaluation Criteria in 
Solid Tumors were analyzed. For all patients, K‑ and NRAS 
status was determined in the tissue by matrix‑assisted laser 
desorption/ionization time of flight mass spectrometry. For 
the detection of RAS mutations in cell‑free tumor DNA also 
defined as circulating tumor DNA (ctDNA), the OncoBEAM® 
RAS CRC kit (Sysmex Inostics) was used. A total of 6/31 tissue 
samples expressed wild‑type KRAS, whereas 25/31 presented 
mutations. In addition, 7/31 plasma samples expressed 
wild‑type KRAS, mutations were detected in 22/31 patients, 
and for 2/31 patients, the test did not provide a conclusive result. 
A total of 24/31 patients expressed wild‑type NRAS, 6/31 had 
mutations and 1/21 was not informative. For the KRAS muta‑
tional status, a moderate concordance (agreement, 85.18%; 
Cohen's k, 0.513) between the tissue and plasma analysis was 
observed; for NRAS, a fair agreement (agreement, 83.33%; 
Cohen's k, 0.242) was obtained. In conclusion, both tissue and 
plasma analyses should be performed for the management of 
patients with mCRC. To better exploit the beads, emulsions, 
amplification, magnetics (BEAMing) technique in the clinical 
setting, studies aimed at determining the RAS status to monitor 
therapy and during follow‑up are warranted.
Introduction
Colorectal cancer (CRC) represents the third most frequent 
tumor worldwide and the second cause of cancer‑related death, 
with 1.8 million cases and 862,000 deaths in 2018 according to 
the World Health Organization estimates (1). Despite advances 
in early diagnosis and treatment, the mortality rate is still high 
due to the development of distant metastases as synchronous 
(in ~20.00% of patients) (2) or metachronous (~40.00% of 
patients) disease (3). Patients with metastatic (m)CRC are 
generally treated with surgery and/or systemic therapy carried 
out using either standard chemotherapy, biological agents or 
a combination of the two methods (4). Considering targeted 
therapy with biological agents, certain patients will respond 
to therapy, whereas others will not due to their genetic 
features (5).
A previous study has demonstrated that mCRC is charac‑
terized by a high frequency of mutations in the RAS gene that 
are the main determinants of the failure of anti‑EGFR‑based 
therapy such as cetuximab and panitumumab (6). Therefore, 
patients with mCRC are routinely screened for BRAF, KRAS 
and NRAS mutations to select the appropriate patients who 
are more likely to have a positive response when treated with 
anti‑EGFR (7‑9). The most frequent mutations associated with 
a poor response to EGFR therapy are located in KRAS exon 2 
(codons 12 and 13, 40.00% of patients), although other codons 
(59 and 61 in exon 3, 117 and 146 in exon 4) may be affected, 
as well as mutations in NRAS (codons 12, 13, 59, 61, 117 and 
146) (10‑14). RAS status is currently determined in tissue 
samples, either from the primary tumor or from metastasis 
obtained during biopsy or surgery.
Since patients with mCRC patients are characterized by 
poor health conditions, multiple biopsies should be avoided; 
however, it has been demonstrated that a single tissue 
biopsy may not be representative of the whole tumor due to 
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intratumoral heterogeneity (15). In addition, tissue biopsy 
cannot be used in these patients for disease monitoring for 
the same reason. Based on this, the concept of liquid biopsy 
has been proposed as a surrogate for a tissue sample (16‑22). 
In previous years technological improvements have enabled 
the study of circulating tumor cells (CTCs) and circulating 
tumor DNA (ctDNA) in the peripheral blood samples of 
patients with advanced cancers (23,24). Previous studies have 
demonstrated that ctDNA levels are associated with clinico‑
pathological and biological features such as tumor histological 
type, stage, burden, blood vessel proximity, apoptotic rate and 
metastatic potential (17,25‑28). Among patients with mCRC, 
it has been demonstrated that a high proportion of patients 
(86.00‑100.00%) is characterized by detectable ctDNA in 
plasma, and that 1.90‑27.00% of total ctDNA harbor different 
mutations (26).
The aims of the present study were as follows: i) To analyze 
the concordance between KRAS and NRAS mutational status 
evaluated in the tissue and the plasma from a cohort of patients 
with mCRC (synchronous or metachronous); ii) to evaluate the 
association between KRAS and NRAS mutations in the ctDNA 
and patient clinicopathological features; and iii) to analyze 
the mutant allele fraction (MAF) distribution in the plasma 
samples and identify potential clinical associations.
Materials and methods
Patients. The study cohort included 31 patients with 
mCRC enrolled at Medical Oncology Unit, Azienda 
Ospedaliero‑Universitaria Careggi (Florence, Italy) between 
January 2017 and August 2018 following written informed 
consent and approval from the Ethical Committee of Azienda 
Ospedaliero‑Universitaria Careggi (approval no. BIO.16.028, 
25/10/2016). All patients were previously diagnosed with clin‑
ical Tumor‑Node‑Metastasis stage IV (29) and had measurable 
disease according to the Response Evaluation Criteria in Solid 
Tumors version 1.1 (30).
Tissue samples. For all patients, KRAS and NRAS status had 
been previously determined in tissue biopsies of either primary 
tumors or metastases by using the Myriapod® Colon Status 
kit (Diatech Pharmacogenetics Srl), which allows the detec‑
tion of 216 mutations in oncogenes responsible for colorectal 
cancerogenesis (KRAS, BRAF, PIK3CA, NRAS) using the 
genotyping platform MassARRAY® system (Sequenom, Inc.) 
based on matrix‑assisted laser desorption ionization‑time of 
flight (MALDI‑TOF) mass spectrometry.
Selection of biological samples and DNA extraction. 
Hematoxylin‑eosin sections from biopsies of neoplastic 
colorectal tissues were obtained from the archive of 
the Pathological Anatomy depar tment of Azienda 
Ospedaliero‑Universitaria Careggi and then revised by two 
experienced pathologists. Only sections containing ≥100 
neoplastic cells were selected. Corresponding formalin‑fixed 
paraffin‑embedded blocks were obtained and 10‑µm tissue 
sections were cut, deparaffinized with solvent, rinsed in alcohol 
and dried before processing. DNA was extracted from tissue 
sections a using MagCore Genomic DNAFFPE One‑Step kit 
(RBC Bioscience Corp.) and then analyzed for quality and 
concentration using a spectrophotometer. If the quality was 
optimal and the concentration was between 2.5‑25.0 ng/ml, 
the samples were amplified.
DNA Amplification. DNA was amplified by multiplex‑PCR 
using the Master Amp‑Mix amplification mixture (Diatech 
Pharmacogenetics Srl) in order to obtain fragments comprising 
all polymorphic sites of interest. The reaction mixture 
contained 1.3 µl water, 0.5 µl PCR buffer, 0.4 µl MgCl2, 0.1 µl 
dNTP mix and 0.2 µl PCR enzyme. All PCR mixes were 
placed on a plate and added to a negative control (2 µl water), a 
sample (2 µl extracted DNA) and a positive control (2 µl human 
wild‑type control DNA provided with the kit). Following spin‑
ning the reaction mixture by brief centrifugation at maximum 
speed, the plate was put in a thermocycler with the following 
amplification profile: 95˚C for 2 min; followed by 45 cycles of 
95˚C for 30 sec, 56˚C for 30 sec and 72˚C for 60 sec; 72˚C for 
5 min; 4˚C for 5 min; and hold at 10˚C.
Treatment with shrimp alkaline phosphatase (SAP) and iPLEX 
extension. Following the amplification, the amplification prod‑
ucts were treated with SAP (provided with the kit) to remove 
nucleotide residues. A SAP cocktail (SAP‑Mix) containing 
1.53 ml water, 0.17 ml SAP Buffer and 0.30 ml SAP Enzyme 
was prepared for each sample. The samples were added to the 
SAP‑Mix and placed in a thermocycler with the following 
conditions: 37˚C for 40 min; 85˚C for 5 min; 4˚C for 5 min; and 
hold at 10˚C. Subsequently, each sample was extended using a 
Master Ext‑Mix extension mixture. Each mixture comprised 
0.56 ml water, 0.20 µl Buffer Plus, 0.20 ml Termination mix 
and 0.04 ml Thermosequenase for each sample reaction. 
The samples were placed in a thermocycler with the Master 
Ext‑Mix and processed under the following thermocycling 
conditions: 94˚C for 30 sec; followed by 40 cycles of 94˚ for 
5 sec, 5 cycles of 52˚C for 5 sec and 5 cycles of 80˚C for 5 sec; 
72˚C for 3 min; 4˚C for 5 min; and hold at 10˚C.
Spectra acquisition and analysis. Once the extension reac‑
tion was completed, the reaction products were dispensed on 
a SpectroCHIP® II G96 using the Nanodispenser RS‑1000® 
Instrument. The SpectroCHIP was then placed in the 
MassARRAY® Analyzer 4 Instrument for spectra acquisition. 
The generated spectra were analyzed using the MassARRAY® 
database with iGenetics® Myriapod® software version 5.1 
(Diatech Pharmacogenetics Srl).
Blood sample collection. Peripheral blood (8 ml) was collected 
from each patient enrolled in the study in K2 EDTA BD 
Vacutainer® collection tubes (BD Biosciences) immediately 
before starting therapy. The plasma was isolated within 4 h 
according to the Sysmex‑Inostics protocol for the determina‑
tion of KRAS and NRAS status with the OncoBEAM® RAS 
CRC assay (Sysmex Inostics). The plasma samples were stored 
at ‑80˚C.
ctDNA extraction and purification. ctDNA was extracted 
from the plasma and purified using a QIAamp® Circulating 
Nucleic Acid kit and QIAvac24 plus (both from Qiagen 
GmbH) according to the manufacturer's protocol with slight 
modifications as indicated by Sysmex Inostics.
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BEAMing assay. For the detection of RAS mutations in 
the ctDNA, OncoBEAM® RAS CRC kit (Sysmex Inostics) 
was used according to the manufacturer's instructions. 
The ctDNA samples were amplified with a multiplex PCR 
performed as follows: 98˚C for 30 sec; followed by 21 cycles 
of 98˚C for 15 sec, 60˚C for 25 sec and 72˚C for 25 sec; 72˚C 
for 35 sec; and hold at 4˚C. The multiplex PCR was followed 
by pooling and dilution with 1X pH 8.0 TE buffer to get the 
optimal amount of PCR product for each codon. The diluted 
samples together with specific positive and negative controls 
[part of the OncoBEAM® RAS CRC kit, (Sysmex Inostics 
GmbH) and carrying specific mutations and no template, 
respectively] were used for emulsion PCR. Following cycling, 
magnetic beads bound to the amplicons were retrieved 
through a breaking phase followed by the hybridization 
step carried out with specific fluorescent probes for further 
detection by Cube6i flow cytometer (Sysmex Inostics). The 
breaking phase was carried out according to the manufac‑
turer's protocol provided with the OncoBEAM® RAS CRC 
kit using a magnet and two buffers, Breaking Buffer 1 and 
2, provided with the kit. The hybridization step performed 
as follows: 70˚C for 30 sec; gradual decrease from 70˚C to 
24˚C with a 3% ramp rate; 24˚C for 1 min; and hold at 21˚C. 
After the completion of the run, the data were exported and 
analyzed by FCS Express version 5.0 software (Denovo 
software; Sysmex Inostics).
Statistical analysis. The demographic, clinical and biological 
characteristics of the patients are presented as frequencies 
and percentages. Continuous variables are presented as the 
median (range of variation). To evaluate the associations 
between RAS mutational status and clinicopathological 
features, parametric (Fisher's exact) and non‑parametric 
(Kruskal‑Wallis) tests were used as appropriate. Data were 
analyzed using the statistical software Stata 9.1 (StataCorp 
LP). A two‑sided P value ≤0.05 was considered to indicate 
a statistically significant difference. For categorical vari‑
ables, the samples were classified as follows: Sex, male vs. 
female; localization of the primary tumor, right colon vs. left 
colon vs. rectum; pathological stage at the time of ctDNA 
analysis, relapse vs. newly diagnosed stage IV tumor; 
histological type, adenocarcinoma vs. mucinous adenocar‑
cinoma; grading, G2 vs. G3; number of metastatic sites at 
the time of ctDNA analysis, 1 vs. 2 vs. 3 vs. >3; surgery for 
primary tumor, yes vs. no. The percentage of agreement was 
evaluated according to the Cohen's κ of concordance and its 
95.00% confidence interval.
Results
Clinical characteristics. In the present study, a total of 
31 patients were enrolled (16 female, 15 male) with a mean age 
67 years (range, 46‑85 years) and a histologically diagnosed 
mCRC not treated for the metastatic disease. The primary 
tumor was mainly localized in the colon (80.64%) with a 
similar distribution between the left and right colon. Among 
the patients, 64.52% received surgery with curative intent for 
the primary disease and developed metachronous metastases. 
The main demographic and clinicopathological features of the 
cohort are presented in Table I.
RAS mutational status in tissue samples. Molecular deter‑
mination of RAS status in paraffin‑embedded samples was 
performed using primary tumor samples in 74.19% of the 
patients and in metastatic tissues in the remaining 25.81% of 
the patients. The analysis was performed by MALDI‑TOF 
mass spectrometry associated to single base extension tech‑
nology and provided conclusive results for all patients; six 
samples (19.35%) expressed the wild‑type form of KRAS, and 
25 samples (80.65%) harbored mutations (Table II). The same 
analysis was performed for NRAS, showing the presence of 
Table I. Demographic and clinicopathological characteristics 
of the study cohort.
Characteristic No. of patients (%)
Sex 
  Female 16 (51.61)
  Male 15 (48.39)
Localization 
  Left colon 12 (38.71)
  Right colon 13 (41.94)
  Rectum 6 (19.35)
Pathological stage at the
time of ctDNA analysis 
  Synchronous 18 (58.06)
  Metachronous 13 (41.94)
Histological type 
  Adenocarcinoma 24 (87.10)
  Mucinous adenocarcinoma 7 (12.90)
Grading 
  G2 19 (61.29)
  G3 3 (9.68)
  Undefined 9 (29.03)
Metastatic sites at the time of
ctDNA analysis 
  Only liver 8 (25.81)
  Only lung 1 (3.23)
  Peritoneum  4 (12.90)
  Multiple 18 (58.06)
Number of metastatic sites at the
time of ctDNA analysis 
  1 13 (41.93)
  2 12 (38.71)
  ≥3 6 (19.36)
Surgery for primary tumor 
  No 11 (35.48)
  Yes 20 (64.52)
Tissue used for molecular analysis of
RAS mutational status 
  Primary tumor 23 (74.19)
  Metastasis 8 (25.81)
ctDNA, circulating tumor DNA.
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a mutation in only one patient (96.77% wild‑type and 3.23% 
mutated) (Table II).
RAS mutational status in plasma samples. RAS mutational 
status was analyzed using BEAMing technology. Of the 31 
samples analyzed, wild‑type KRAS was identified in seven 
patients, whereas mutations were detected in 22 patients 
(17 in codon 12, four in codon 13, one in codon 146); for 
two patients, an informative result could not be obtained. 
Regarding NRAS analysis, the wild‑type form of the gene 
was observed in 24 patients, two patients harbored a muta‑
tion in codon 12, four harbored a mutation in codon 61 and 
the data for one patient was not informative (Table III). 
Fig. 1 demonstrates representative plots obtained using the 
BEAMing assay (left plots, ‘universal signal’ vs. ‘mutant 
signal’; right plots, ‘wild‑type signal’ vs. ‘mutant signal’). In 
Fig. 1A, the results of a no template control are presented, 
and no signal is present in the right plot. By contrast, in 
the two plots in Fig. 1B representing the positive control, 
an intense signal in the gate corresponding to mutant beads 
(mtP3) can be observed. In Fig. 1C and D, two representative 
samples classified as wild‑type and mutated, respectively, 
are demonstrated: In the former, almost no signal is present 
in mtP3 gate, whereas in the latter, the presence of the 
mutation is marked by the black dots in the mrP3 quadrant 
(see arrow).
The technique used to analyze these plasma samples from 
patients with mCRC did not provide the result of the test as an 
absolute number of RAS mutated alleles, but as the mutant allele 
fraction (MAF), which is the ratio (expressed as a percentage) 
of mutated and wild‑type RAS alleles (Table IV). Analysis of 
the mutated samples (mutated beads ≥40) revealed large vari‑
ability among patients, and the mean number of mutant beads 
was 6,047.909±1.594 (n=22) for KRAS and 281±0.103 (n=5) 
for NRAS (Table IV, last row).
For the majority of the patients, a single mutation either in 
KRAS or NRAS was detected (28/31), whereas three patients 
presented with mutations in both genes. Notably, in two of 
these three patients (patients COL002 and COL018), a KRAS 
mutation was also identified in the tissue sample, whereas 
NRAS mutations were detected only in the plasma. In both 
cases, the allele frequency of KRAS (MAF, 21.226 and 7.645) 
was higher compared with that of NRAS (MAF, 0.031 and 
0.344); this result was not unexpected since the BEAMing 
technique exhibited higher sensitivity compared with that of 
MALDI‑TOF mass spectrometry, and thus it is possible that a 
number of the mutations were not detected in the tissue samples 
if their frequency was low, as observed in these patients.
The concordance between the results obtained in the tissue 
and plasma samples was subsequently evaluated (Table V). 
Analysis of the data using Cohen's κ revealed a moderate 
concordance between tissue and plasma analysis of KRAS 
mutational status (agreement, 85.18%; Cohen's κ, 0.513); for 
NRAS mutational status a fair agreement was found (agree‑
ment, 83.33%; Cohen's κ, 0.242)
In order to evaluate the association between RAS muta‑
tional status and patient clinicopathological features, the 
Table II. KRAS and NRAS analysis of tissue samples.
RAS status No. of patients (%)
Wild‑type KRAS 6 (19.35)
Mutated KRAS 25 (80.65)
  Exon 2 codon 12 19 (76.00)
    G12A 4 
    G12C 3 
    G12D 10 
    G12V 2 
  Exon 2 codon 13 5 (20.00)
    G13D 4 
    G13V 1 
  Exon 3 codon 59 0 (0.00)
  Exon 3 codon 61 0 (0.00)
  Exon 4 codon 117 0 (0.00)
  Exon 4 codon 146 1 (4.00)
    A146P 1 
Wild‑type NRAS 30 (96.77)
Mutated NRAS 1 (3.23)
  Exon 2 codon 12 1 (100.00)
    G12D 1
  Exon 2 codon 13 0 (0.00)
  Exon 3 codon 59 0 (0.00)
  Exon 3 codon 61 0 (0.00)
  Exon 4 codon 117 0 (0.00)
  Exon 4 codon 146 0 (0.00)
  Undefined 0 (0.00)
Table III. KRAS and NRAS analysis of plasma samples.
RAS status No. of patients (%)
Wild‑type KRAS 7 (22.58)
Mutated KRAS 22 (77.42)
  Exon 2 codon 12 17 (77.27)
  Exon 2 codon 13 4 (18.18)
  Exon 3 codon 59 0 (0.00)
  Exon 3 codon 61 0 (0.00)
  Exon 4 codon 117 0 (0.00)
  Exon 4 codon 146 1 (4.55)
Not informative  2
  Total 31
Wild‑type NRAS 24 (77.42)
Mutated NRAS 6 (22.58)
  Exon 2 codon 12 2 (33.33)
  Exon 2 codon 13 0 (0.00)
  Exon 3 codon 59 0 (0.00)
  Exon 3 codon 61 4 (66.67)
  Exon 4 codon 117 0 (0.00)
  Exon 4 codon 146 0 (0.00)
  Not informative  1
  Total 31
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Figure 1. Representative plots obtained by BEAMing assay. In the left plot of each panel ‘universal signal’ vs. ‘mutant signal’ is reported, whereas in the right 
plot, ‘wild‑type signal’ vs. ‘mutant signal’ is presented. (A) Negative control; (B) PC; mutant beads, 844; mutant fraction, 0.46%; (C) WT; mutant beads, 14; 
mutant fraction, 0.02%; (D) MUT; mutant beads, 14,746; mutant fraction, 7.645 (see arrow). EB, extended beads; NEB, non‑extended beads; wt, wild‑type; mx, 
mutant and wild‑type; mt, mutant; NTC, no template control; PC, positive control; WT, wild‑type sample; MUT, mutant sample.
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samples were divided into two groups: Wild‑type and mutated 
(either K‑ or NRAS). No significant associations were identi‑
fied between the two groups (Table VI).
Discussion
Emerging evidence has demonstrated the importance of liquid 
biopsy as a surrogate of standard tissue biopsies for diagnostic 
purposes as well as for monitoring patients with mCRC (16‑21). 
In particular, in mCRC patients, multiple biopsies should be 
avoided due to their poor general health conditions.
In 2016, a meta‑analysis reported that ctDNA may 
represent an indicator for poor prognosis, including both 
recurrence‑free survival and overall survival (OS), in 
patients with stage I‑IV CRC (28). A study performed 
by Spindler et al (31) demonstrated that an increase in 
ctDNA reduced the progression‑free survival (PFS) and 
OS (defined as the months elapsed from the first diagnosis 
and the progression of the disease or death of the patient, 
respectively) time with a hazard ratio of 1.4 (95% CI, 1.1‑1.7; 
P=0.03) and 1.6 (95% CI, 1.3‑2.0; P<0.0001), respectively. 
In addition, their study revealed that the evaluation of KRAS 
mutations in the plasma provided additional information on 
the patient outcome (31). A recent study performed a parallel 
analysis of ctDNA and circulating tumor cells (CTCs) and 
demonstrated that the former represented an improved 
tool for the management of patients with CRC since CTCs 
were not detected in all samples in contrast to ctDNA, and 
a low volume of blood was sufficient for the molecular 
analysis (32).
Table IV. OncoBEAM® RAS colorectal cancer test results.
 KRAS NRAS
 ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑ ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑
Patient ID Mutant beads (n) MAF Test result Mutant beads  (n) MAF Test result
COL001 8 0.013 Wild‑type 13 0.041 Wild‑type
COL002 97,951 21.226 Mutation detected 65 0.031 Mutation detected
COL003 6,862 5.610 Mutation detected 6 0.011 Wild‑type
COL004 36,785 13.006 Mutation detected 8 0.009 Wild‑type
COL005 12,879 6.759 Mutation detected 22 0.020 Wild‑type
COL006 1,516 0.998 Mutation detected 17 0.058 Wild‑type
COL007 32,095 5.262 Mutation detected 4 0.002 Wild‑type
COL008 6 0.005 Wild‑type 49 0.053 Mutation detected
COL009 43,649 9.861 Mutation detected 7 0.002 Wild‑type
COL010 7 0.009 Wild‑type 2 0.005 Wild‑type
COL011 691 0.653 Mutation detected 0 0.000 Wild‑type
COL012 51,794 11.216 Mutation detected 4 0.001 Wild‑type
COL013 137 0.144 Mutation detected 6 0.015 Wild‑type
COL014 70 0.068 Mutation detected 9 0.022 Wild‑type
COL015 29 0.012 Wild‑type 10 0.007 Wild‑type
COL016 292 0.045 Mutation detected 7 0.002 Wild‑type
COL017 29,038 28.149 Mutation detected 2 0.002 Wild‑type
COL018 14,746 7.645 Mutation detected 164 0.344 Mutation detected
COL019 9,023 5.455 Mutation detected 3 0.017 Wild‑type
COL020 45 0.056 Mutation detected NI NI NI
OB3 61 0.053 Mutation detected 22 0.025 Wild‑type
OB4 7,861 11.211 Mutation detected 1 0.002 Wild‑type
OB5 NI NI NI 1 0.003 Wild‑type
OB7 2 0.005 Wild‑type 0 0.000 Wild‑type
OB8 1,178 0.918 Mutation detected 6 0.005 Wild‑type
OB9 10,639 4.693 Mutation detected 5 0.004 Wild‑type
OB10 42 0.017 Mutation detected 429 0.469 Mutation detected
OB11 24 0.028 Wild‑type 246 0.516 Mutation detected
OB12 15 0.013 Wild‑type 5 0.009 Wild‑type
OB14 NI NI NI 9 0.023 Wild‑type
OB15 0 0.000 Wild‑type 7 0.012 Wild‑type
Mean ± SEM 6,047.909±1.594   281±0.103  
MAF, mutant allele fraction; NI, not informative; SEM, standard error of the mean; detected mutations are indicated in bold.
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Overall, the frequency of K‑ and N‑RAS mutations in the 
present study was higher compared with the one expected to be 
observed in the general population, although notably, for a part 
of the cohort, one of the inclusion criteria was the presence of 
KRAS mutations.
In the cohort of patients analyzed in this study, coexistence 
of K‑ and N‑RAS mutations was observed in 3/31 patients 
(9.70%). For two patients, MAF values were higher for KRAS 
compared with those for NRAS, whereas an opposite trend 
was observed in the third patient. Although K‑ and N‑RAS 
mutations are generally mutually exclusive, the high sensitivity 
of BEAMing may allow the identification of subclonal 
mutations that may have been missed with other techniques. 
However, since these mutations are present at in a small 
proportion of patients their biological and clinical relevance 
requires further investigation. It may have been be interesting 
to apply the BEAMing technology to the tissue samples to 
evaluate whether such subclonal mutations were present in the 
tumor tissues as well as in the plasma, but it was not possible 
to identify them due to the lower sensitivity of the standard 
techniques applied in the analyses of tissue samples.
The results of the present study identified a concordance 
between BEAMing and MALDI‑TOF, as previously reported 
in other studies (33,34). Overall, for the KRAS mutational 
status, five samples were not in accordance. The possible 
causes of such discordance were subsequently explored. In four 
patients, a mutation was detected in the tissue, but not in the 
plasma; this observation may be explained by the elimination 
of sensitive clones by the treatment if the two analyses were 
performed at different times (as in patients OB7 and OB15); 
on the other hand, the discrepancy may also have occurred due 
to the low tumor burden if the two analyses were performed at 
Table V. Concordance between tissue and plasma analysis of RAS mutational status.
 KRAS NRAS
 ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑ ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑
Patient ID Tissue Plasma Concordance Tissue Plasma Concordance
COL001 G12D wt no wt wt yes
COL002 G12C Cd12 yes wt Cd12 no
COL003 G12A Cd12 yes wt wt yes
COL004 G12D Cd12 yes wt wt yes
COL005 G13D Cd13 yes wt wt yes
COL006 G12C Cd12 yes wt wt yes
COL007 G12D Cd12 yes wt wt yes
COL008 wt wt yes G12D CD12 yes
COL009 G13D Cd13 yes wt wt yes
COL010 G13D Cd13 yes wt wt yes
COL011 G12D Cd12 yes wt wt yes
COL012 G12A Cd12 yes wt wt yes
COL013 G13D Cd13 yes wt wt yes
COL014 G12A Cd12 yes wt wt yes
COL015 G13V wt no wt wt yes
COL016 G12D Cd12 yes wt wt yes
COL017 G146P Cd146 yes wt wt yes
COL018 G12D Cd12 yes wt CD61 no
COL019 G12C Cd12 yes wt wt yes
COL020 G12D Cd12 yes wt NI NA
OB3 G12D Cd12 yes wt wt yes
OB4 G12D Cd12 yes wt wt yes
OB5 wt NI NA wt wt yes
OB7 G12D wt no wt wt yes
OB8 G12V Cd12 yes wt wt yes
OB9 G12A Cd12 yes wt wt yes
OB10 wt Cd12 no wt CD61 no
OB11 wt wt yes wt CD61 no
OB12 wt wt yes wt wt yes
OB14 wt NI NA wt CD61 no
OB15 G12V wt no wt wt yes
NI, not informative; NA, not applicable (since one of the evaluations is missing); wt, wild‑type. Detected mutations are indicated in bold.
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similar times (as in patients COL001 and COL015). COL001 
and COL015, harboring KRAS mutations in the tissue, but not 
in the plasma, had mucinous tumors and underwent surgical 
resection with curative intent. In addition, the analysis of 
radiographic images captured on a date close to the blood 
collection demonstrated that the two patients exhibited a 
low tumor burden (localization of the disease limited to the 
peritoneum in one patient and relatively small metastases in 
the liver in the other). These results were in accordance with 
those obtained in a large multicenter prospective cohort, which 
demonstrated that surgery of the primary tumor, absence of 
liver metastases and peritoneal localization were significantly 
associated with inconclusive results in the plasma (35).
In one patient (OB10), a mutation was detected in the 
plasma, but not in the tissue. Since the BEAMing assay is more 
sensitive compared with MALDI‑TOF mass spectrometry, 
the mutation may have been missed due to the low MAF 
(0.017). Another explanation may be that mutations may have 
developed a long time after diagnosis and evaluation of RAS 
mutational status in tissue samples, and if tissue analysis was 
performed using tissues obtained during a biopsy, the mutation 
may have been missed due to the heterogeneity and the low 
tumor cell fraction in the specimen. This patient had a long 
and satisfactory response (2 years) to therapy that has been 
recently published as a case report (36) and may represent an 
example of rechallenge failure due to molecular determinants. 
In particular, since the patient exhibited a complete response 
to Cetuximab, after two years, the treatment was repeated 
using the same drug, but the disease rapidly progressed; the 
analysis of plasma in this case may have helped determine a 
different schedule of treatment.
In addition, for NRAS, five samples were not in accordance; 
a mutation was detected in the plasma, whereas the tissues was 
classified as harboring wild‑type NRAS. This discrepancy may 
be explained as aforementioned.
A potential limitation of the present study was the absence 
of validation of the data obtained through BEAMing with a 
different technique. In the present study, it was not possible 
Table VI. Associations between RAS mutational status and clinicopathological features.
 RAS mutational status, n (%)
 ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑
Clinical feature n Wild‑type Mutated P‑value
Sex    0.355a
  Male 15 3 (20.00) 12 (80.00) 
  Female 16 3 (18.75) 13 (81.25) 
Age, years    0.221b
  Mean, 67 (range, 46‑85) 31 6 (19.35) 25 (80.65) 
Localization    0.333a
  Right colon 13 1 (7.69) 12 (92.31) 
  Left colon 12 3 (25.00) 9 (75.00) 
  Rectum 6 2 (33.33) 4 (66.67) 
Pathological stage at the time of ctDNA analysis    >0.999a
  Synchronous 18 3 (16.67) 15 (83.33) 
  Metachronous 13 3 (23.08) 10 (76.92) 
Histological type    0.287a
  Adenocarcinoma 24 3 (12.50) 21 (87.50) 
  Mucinous adenocarcinoma 7 3 (42.86) 4 (57.14) 
Grading    0.422a
  G1 0 0 (0.00) 0 (0.00) 
  G2 19 3 (15.79) 16 (84.21) 
  G3 3 1 (33.33) 2 (66.67) 
  Undefined 9 2 (22.22) 7 (77.78) 
Number of metastatic sites at the time of ctDNA analysis    0.413a
  1 13 1 (7.69) 12 (92.31) 
  2 12 5 (41.67) 7 (58.33) 
  ≥3 6 0 (0.00) 6 (100.00) 
Surgery for primary tumor    >0.999a
  No 11 3 (27.27) 8 (72.73) 
  Yes 20 3 (15.00) 17 (85.00) 
aFisher's exact test; bKruskal‑Wallis test. ctDNA, circulating tumor DNA.
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to obtain such confirmation, since the amount DNA available 
from each patient was not enough to perform other experiments 
with various methodologies, and no additional blood collection 
was performed due to the general conditions of the patients to 
avoid enhancing their discomfort. Such evaluation represents 
a future perspective and will be performed in a further study. 
However, in patients with low MAF (such as patient OB10) 
with a value close to the cut‑off, BEAMing analysis was 
performed twice to verify the result since additional methods 
could not be performed.
A recent multicenter clinical study performed in Japan 
provided clinical validation of the OncoBEAM® RAS CRC 
assay (37), paving the road to the incorporation of BEAMing 
into clinical practice. The results of the aforementioned study, 
although it was performed on a larger cohort compared to the 
one used in the present study, were in concert with the findings 
of the present study since they obtained an overall concordance 
between tissue and plasma analyses equal to 86.4%.
Overall, the results of the present study identified a certain 
degree of agreement between the two techniques. Based on 
these preliminary data, it is suggested that both analyses should 
be routinely performed to provide clinicians an additional tool 
for the management of patients with mCRC. To confirm these 
results, validation studies on larger cohorts are warranted, as 
well as studies aimed at determining the RAS status to monitor 
therapy and during follow‑up.
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